The Europe Sepsis Diagnostics Market is expected to witness market growth of 7.6% CAGR during the forecast period (2022-2028).
It harms the tissues and organs of its own body. Physicians classify sepsis as a three-staged illness that begins with sepsis and progresses to severe sepsis and lastly septic shock. Severe sepsis is linked to organ failure and a rapid change in the mental status of the patient. Septic shock is a medical emergency classified as severe sepsis with symptoms of aberrant cellular metabolism, rapid drops in blood pressure, and organ malfunction. Sepsis is a dangerous consequence that results from a weakened immune system, making people vulnerable to viral, bacterial, parasitic, fungal, and other illnesses. In hospitals, sepsis is amongst the leading causes of death. When the patient's immune system responds to an infection, chemicals are released by the immune system to treat the infection, resulting in sepsis.
Sepsis creates levels of inflammation as it enters the bloodstream. It produces blood vessel leakage, blood clots, and poor blood flow, denying oxygen and nutrition to the body's vital organs. People with weak immune systems, youngsters, the elderly, and those suffering from chronic illnesses including cancer, AIDS, diabetes, and others are at a higher risk of acquiring sepsis.
According to several surveys, the death rate related to sepsis slowly declining in Germany. This is mostly due to improved healthcare services across the country along with the rising utilization of the sepsis diagnostic approaches. In addition, there is a rising scale of awareness in regional population about the disorder, and health professionals are getting more skilled. As a result of these advancements, diagnosing the condition has become much easier and more efficient.
In addition, developed countries across the region comprise a robust and well-established research and development infrastructure, which has attracted the interest of several foreign firms.
In France, on the other hand, the market is primarily driven by an increase in sepsis cases, along with the increase in the number of diagnostics businesses establishing operations in the country. As per the Pasteur Institute, a non-profit organization committed to conduct research on illnesses and vaccines, sepsis cases are projected to increase in the next 50 years as the aging population grows. This places a significant strain on the healthcare system, driving up demand for sepsis detection and treatment and bolstering the growth of the French sepsis diagnostics market.
The Germany market dominated the Europe Sepsis Diagnostics Market by Country in 2021, and is expected to continue to be a dominant market till 2018; thereby, achieving a market value of $57.2 million by 2028. The UK market is estimated to grow at a CAGR of 6.7% during (2022-2028). Additionally, The France market is expected to exhibit a CAGR of 8.4% during (2022-2028).
Based on Method, the market is segmented into Conventional and Automated. Based on Test Type, the market is segmented into Laboratory Tests and Point-of-Care Tests. Based on Pathogen, the market is segmented into Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, and Others. Based on Product, the market is segmented into Blood Culture Media, Assays & Reagents, Instruments, and Software. Based on End-User, the market is segmented into Hospitals & specialty clinics, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes. Based on Technology, the market is segmented into Blood Culture, Immunoassays, Molecular Diagnostics, Flow Cytometry, Microfluidics, and Biomarkers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.
By Method
By Country
It harms the tissues and organs of its own body. Physicians classify sepsis as a three-staged illness that begins with sepsis and progresses to severe sepsis and lastly septic shock. Severe sepsis is linked to organ failure and a rapid change in the mental status of the patient. Septic shock is a medical emergency classified as severe sepsis with symptoms of aberrant cellular metabolism, rapid drops in blood pressure, and organ malfunction. Sepsis is a dangerous consequence that results from a weakened immune system, making people vulnerable to viral, bacterial, parasitic, fungal, and other illnesses. In hospitals, sepsis is amongst the leading causes of death. When the patient's immune system responds to an infection, chemicals are released by the immune system to treat the infection, resulting in sepsis.
Sepsis creates levels of inflammation as it enters the bloodstream. It produces blood vessel leakage, blood clots, and poor blood flow, denying oxygen and nutrition to the body's vital organs. People with weak immune systems, youngsters, the elderly, and those suffering from chronic illnesses including cancer, AIDS, diabetes, and others are at a higher risk of acquiring sepsis.
According to several surveys, the death rate related to sepsis slowly declining in Germany. This is mostly due to improved healthcare services across the country along with the rising utilization of the sepsis diagnostic approaches. In addition, there is a rising scale of awareness in regional population about the disorder, and health professionals are getting more skilled. As a result of these advancements, diagnosing the condition has become much easier and more efficient.
In addition, developed countries across the region comprise a robust and well-established research and development infrastructure, which has attracted the interest of several foreign firms.
In France, on the other hand, the market is primarily driven by an increase in sepsis cases, along with the increase in the number of diagnostics businesses establishing operations in the country. As per the Pasteur Institute, a non-profit organization committed to conduct research on illnesses and vaccines, sepsis cases are projected to increase in the next 50 years as the aging population grows. This places a significant strain on the healthcare system, driving up demand for sepsis detection and treatment and bolstering the growth of the French sepsis diagnostics market.
The Germany market dominated the Europe Sepsis Diagnostics Market by Country in 2021, and is expected to continue to be a dominant market till 2018; thereby, achieving a market value of $57.2 million by 2028. The UK market is estimated to grow at a CAGR of 6.7% during (2022-2028). Additionally, The France market is expected to exhibit a CAGR of 8.4% during (2022-2028).
Based on Method, the market is segmented into Conventional and Automated. Based on Test Type, the market is segmented into Laboratory Tests and Point-of-Care Tests. Based on Pathogen, the market is segmented into Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, and Others. Based on Product, the market is segmented into Blood Culture Media, Assays & Reagents, Instruments, and Software. Based on End-User, the market is segmented into Hospitals & specialty clinics, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes. Based on Technology, the market is segmented into Blood Culture, Immunoassays, Molecular Diagnostics, Flow Cytometry, Microfluidics, and Biomarkers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Method
- Conventional
- Automated
- Laboratory Tests
- Point-of-Care Tests
- Bacterial Sepsis
- Fungal Sepsis
- Viral Sepsis
- Others
- Blood Culture Media
- Assays & Reagents
- Instruments
- Software
- Hospitals & specialty clinics
- Pathology & Reference Laboratories
- Research Laboratories & Academic Institutes
- Blood Culture
- Immunoassays
- Molecular Diagnostics
- Flow Cytometry
- Microfluidics
- Biomarkers
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- BioMérieux S.A.
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- DiaSorin S.p.A.
- Bruker Corporation
- Siemens Healthineers AG
- Danaher Corporation
- Quidel Corporation
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Sepsis Diagnostics Market by Method
Chapter 5. Europe Sepsis Diagnostics Market by Test Type
Chapter 6. Europe Sepsis Diagnostics Market by Pathogen
Chapter 7. Europe Sepsis Diagnostics Market by Product
Chapter 8. Europe Sepsis Diagnostics Market by End-User
Chapter 9. Europe Sepsis Diagnostics Market by Technology
Chapter 10. Europe Sepsis Diagnostics Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- BioMérieux S.A.
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- DiaSorin S.p.A.
- Bruker Corporation
- Siemens Healthineers AG
- Danaher Corporation
- Quidel Corporation
Methodology
LOADING...
